Dr Sam Orange
Dr Morven Brown
Dr Kate Hallsworth
Dr Fiona Malcomson
Professor Bernard Corfe
et al. | Co-development of a programme to improve physical activity support for women after breast cancer treatment: a pre-protocol for PURE-EX | 2025 |
|
Dr David Austin
Rebecca Maier
Dr Nicola Cresti
Dr Mark Verrill
Dr Wendy Osborne
et al. | Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial | 2024 |
|
Dr Jingky Lozano-Kuehne
Dr Nicola Cresti
Professor Ruth Plummer
| Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer | 2022 |
|
Dr Nicola Cresti
| A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer | 2020 |
|
Ali Kucukmetin
Dr Nicola Cresti
Dr Rachel O'Donnell
| BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature | 2020 |
|
Dr Nicola Cresti
Dr Yvette Drew
| First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor | 2020 |
|
Dr Nicola Cresti
Professor Ruth Plummer
| A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine | 2019 |
|
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al. | Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil | 2014 |
|
Professor Ruth Plummer
Dr Nicola Cresti
Dr Yvette Drew
Dr Peter Stephens
Dr Jared Thornton
et al. | Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma | 2014 |
|
Dr Nicola Cresti
Professor Ruth Plummer
| A phase 1 study of oral rucaparib in combination with carboplatin | 2013 |
|
Dr Nicola Cresti
Dr Yvette Drew
Professor Ruth Plummer
| A phase I study of oral rucaparib in combination with carboplatin | 2013 |
|
Dr Nicola Cresti
Dr Chris Plummer
| Cardiac troponin release following standard dose anthracycline-based adjuvant chemotherapy | 2013 |
|
Dr Nicola Cresti
Professor Ruth Plummer
| Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study | 2012 |
|
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al. | Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy | 2011 |
|
Dr Nicola Cresti
Dr David Jamieson
| The pharmacology of trastuzumab and its use in breast cancer | 2010 |
|
Dr David Jamieson
Dr Nicola Cresti
Dr Mark Verrill
Professor Alan Boddy
| Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma | 2009 |
|
